



UNITED STATES PATENT AND TRADEMARK OFFICE

UNDER SECRETARY OF COMMERCE FOR INTELLECTUAL PROPERTY AND
DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUNE 29, 2020

PTAS

JANET TSE
C/O GENENTECH, INC.
1 DNA WAY, M.S. 49
SOUTH SAN FRANCISCO, CA 94080

506128025

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT RECORDATION BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE ASSIGNMENT RECORDATION BRANCH AT 571-272-3350. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, MAIL STOP: ASSIGNMENT RECORDATION BRANCH, P.O. BOX 1450, ALEXANDRIA, VA 22313.

RECORDATION DATE: 06/26/2020

REEL/FRAME: 053059/0510
NUMBER OF PAGES: 3

BRIEF: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

DOCKET NUMBER: P35574-WO AND P35574-US

ASSIGNOR:
CHENG, YUN-XING

DOC DATE: 06/03/2020

ASSIGNEE:
PHARMARON BEIJING, CO. LTD.
6 TAIHE ROAD
BDA
BEIJING, CHINA 100176

APPLICATION NUMBER: 63035381

FILING DATE: 06/05/2020

PATENT NUMBER:

ISSUE DATE:

TITLE: PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF

APPLICATION NUMBER:
PATENT NUMBER:
PCT NUMBER: CN2019091712
TITLE:

FILING DATE:
ISSUE DATE:

ASSIGNMENT RECORDATION BRANCH
PUBLIC RECORDS DIVISION

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
YUN-XING CHENG	06/03/2020
RECEIVING PARTY DATA	
Name:	PHARMARON BEIJING, CO. LTD.
Street Address:	6 TAIHE ROAD
Internal Address:	BDA
City:	BEIJING
State/Country:	CHINA
Postal Code:	100176
PROPERTY NUMBERS Total: 2	
Property Type	Number
PCT Number:	CN2019091712
Application Number:	63035381
CORRESPONDENCE DATA	
Fax Number:	(650)952-9881
Phone:	6502252906
Email:	jet@gene.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	JANET TSE
Address Line 1:	C/O GENENTECH, INC.
Address Line 2:	1 DNA WAY, M.S. 49
Address Line 4:	SOUTH SAN FRANCISCO, CALIFORNIA 94080
ATTORNEY DOCKET NUMBER:	P35574-WO AND P35574-US
NAME OF SUBMITTER:	JANET TSE
Signature:	/Janet Tse/
Date:	06/26/2020

Total Attachments: 2

source=P35574 yunxing cheng signed assignment#page1.tif

source=P35574 yunxing cheng signed assignment#page2.tif

RECEIPT INFORMATION**EPAS ID:** PAT6174751**Receipt Date:** 06/26/2020

ASSIGNMENT

WHEREAS, **Yun-Xing CHENG** ("ASSIGNOR"), have invented a new and useful invention in

PYRAZOLOPYRIMIDINE SULFONE INHIBITORS OF JAK KINASES AND USES THEREOF

for which an International Patent Application Serial No. PCT/CN2019/091712 (Docket No. **P35574-WO**) has been filed on 18 June 2019; and U.S. Provisional Patent Application Serial No. 63/035381¹ (Docket No. **P35574-US**) has been filed on 5 June 2020¹;

WHEREAS, PHARMARON BEIJING CO., LTD., a corporation having a place of business at 6 Taihe Road, BDA, Beijing, 100176, P.R. China, is desirous of acquiring an interest in and to said invention, and in and to the Letters Patents to be obtained therefor;

NOW, THEREFORE, be it known by all whom it may concern;

That for good and valuable consideration the receipt of which is hereby acknowledged, the undersigned ASSIGNOR(S) have and do hereby sell, assign, transfer and set over unto the said PHARMARON BEIJING CO., LTD., its successors and assigns, the full and exclusive right, title and interest, including all rights under the Paris Convention for the Protection of Industrial Property, in and to said invention, and in and to any and all applications filed and Letters Patents granted and issued therefor, or any continuation, division, renewal, or substitute thereof, and as to Letters Patents any reissue or re-examination thereof, not only for, to, and in the United States of America, its territories and possessions, but for, to and in all other countries; and it has been and is hereby authorized and requested that the appropriate government agencies issue said Letters Patents to said PHARMARON BEIJING CO., LTD. in accordance with this Assignment.


The undersigned ASSIGNOR(S) covenant and agree to cooperate with PHARMARON BEIJING CO., LTD., to enable said PHARMARON BEIJING CO., LTD. to enjoy to the fullest extent the right, title and interest herein conveyed in the United States and foreign countries. Such cooperation by the undersigned ASSIGNOR(S) includes prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance, all to the extent deemed necessary or desirable by said PHARMARON BEIJING CO., LTD., (a) for perfecting the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting applications for reissuance of any of said patents; (d) for interference or other priority proceedings involving said invention; and (e) for legal proceedings involving said invention and any applications therefor and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that the expense incurred by the undersigned ASSIGNOR(S) in providing such cooperation shall be paid for by said PHARMARON BEIJING CO., LTD.

The terms and covenants of this assignment shall inure to the benefit of said PHARMARON BEIJING CO., LTD., its successors, assigns and other legal representatives, and shall be binding upon the undersigned ASSIGNOR(S), their respective heirs, legal representatives and assigns.

The undersigned ASSIGNOR(S) hereby warrant and represent that they have not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

¹Assignor and Assignee hereby authorize Genentech, Inc., and their representatives and assigns to insert the application number and filing date information when they become known.

IN WITNESS WHEREOF I undersign as follows;



June 3, 2020

Yun-Xing CHENG

Date

Mailing address:

6 Taihe Road
BDA, Beijing, 100176
P.R. China

Citizenship: **Canada**